Drug Trial Radar · NCT06607016
A Clinical Trial With KJ103 in Anti-GBM Disease
Last checked: Nov 19, 2026Latest source record: Jun 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Oct 21, 2024
Primary completion
Dec 31, 2025
Study completion Mar 2026
Sponsor
- Lead sponsor
- Shanghai Bao Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 23, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open-label, single-arm Phase II study to evaluate the preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and immunogenicity of KJ103 in patients with anti-GBM disease.
Conditions
- Anti-Glomerular Basement Membrane Disease
Interventions
KJ103 for InjectionDrug
Subjects will administered KJ103 intravenously on D1 and adjunctively on D8
CyclophosphamideDrug
Hence treatment prevents formation of new anti-GBM antibodies.
GlucocorticoidsDrug
Glucocorticoids inhibit the inflammation process.
Plasma exchange (PE)Procedure
PLEX removes the patient\'s pathogenic anti-GBM antibodies, by replacement of deficient plasma with a replacement fluid.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Renal functionTime frame: day 90, day 180
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.